149.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt A?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$146.80
Offen:
$147
24-Stunden-Volumen:
168.96K
Relative Volume:
0.08
Marktkapitalisierung:
$42.05B
Einnahmen:
$7.23B
Nettoeinkommen (Verlust:
$1.41B
KGV:
29.94
EPS:
4.979
Netto-Cashflow:
$1.09B
1W Leistung:
+1.48%
1M Leistung:
+0.33%
6M Leistung:
+33.64%
1J Leistung:
+18.62%
Agilent Technologies Inc Stock (A) Company Profile
Firmenname
Agilent Technologies Inc
Sektor
Branche
Telefon
(408) 345-8886
Adresse
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, NTRA, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
A
Agilent Technologies Inc
|
149.13 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
|
TMO
Thermo Fisher Scientific Inc
|
627.88 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
206.64 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
340.61 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
IQV
Iqvia Holdings Inc
|
269.95 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-08 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-10 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-17 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-05-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | Citigroup | Neutral |
| 2023-05-24 | Bestätigt | Credit Suisse | Outperform |
| 2023-05-24 | Bestätigt | Evercore ISI | Outperform |
| 2023-05-24 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | Bestätigt | Robert W. Baird | Outperform |
| 2023-05-24 | Bestätigt | SVB Securities | Outperform |
| 2023-05-24 | Bestätigt | Stifel | Hold |
| 2023-05-24 | Bestätigt | TD Cowen | Outperform |
| 2023-05-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-05-11 | Eingeleitet | Barclays | Equal Weight |
| 2023-01-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-07-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | Bestätigt | BofA Securities | Buy |
| 2022-02-23 | Bestätigt | Citigroup | Buy |
| 2022-02-23 | Bestätigt | Cowen | Outperform |
| 2022-02-23 | Bestätigt | Evercore ISI | Outperform |
| 2022-02-23 | Bestätigt | Stifel | Hold |
| 2022-02-23 | Bestätigt | Wells Fargo | Overweight |
| 2021-11-23 | Bestätigt | BofA Securities | Buy |
| 2021-11-23 | Bestätigt | Cowen | Outperform |
| 2021-11-23 | Bestätigt | Stifel | Hold |
| 2021-03-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Hochstufung | UBS | Neutral → Buy |
| 2020-11-17 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Neutral |
| 2020-08-19 | Bestätigt | BofA Securities | Neutral |
| 2020-08-19 | Bestätigt | Citigroup | Neutral |
| 2020-08-19 | Bestätigt | Jefferies | Buy |
| 2020-08-19 | Bestätigt | Robert W. Baird | Outperform |
| 2020-08-19 | Bestätigt | SVB Leerink | Outperform |
| 2020-08-19 | Bestätigt | Stifel | Hold |
| 2020-08-19 | Bestätigt | Wells Fargo | Overweight |
| 2020-02-24 | Herabstufung | Needham | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-26 | Bestätigt | Needham | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | UBS | Buy → Neutral |
| 2019-07-16 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | Herabstufung | Barclays | Overweight → Equal Weight |
Alle ansehen
Agilent Technologies Inc Aktie (A) Neueste Nachrichten
Agilent Technologies Inc. stock outperforms competitors on strong trading day - MarketWatch
Jefferies Initiates Agilent Technologies(A.US) With Hold Rating, Announces Target Price $155 - Moomoo
Agilent Technologies stock edges lower as analysts keep upside targets - ad-hoc-news.de
Agilent Technologies stock heads into the open after a 1.2 percent drop - ad-hoc-news.de
Agilent’s CEO and CFO will join a London fireside chat Sept. 23 - Stock Titan
Agilent to Participate in J.P. Morgan U.S. All Stars Conference - Business Wire
Form 8K Agilent Technologies For: 10 September By Investing.com - Investing.com Canada
Agilent Technologies stock dips after insider buy and Q3 earnings strength - ad-hoc-news.de
Agilent files Form 3 initial beneficial ownership statement for director Glenn S. Boehnlein - Bitget
Insider Unloading: Mikael Dolsten Sells $95K Worth Of Agilent Technologies Shares - Benzinga
Major Purchase Alert: Glenn Boehnlein Invests $119K In Agilent Technologies Stock - Benzinga
Director at Agilent Technologies (A) gets 817-share stock grant - Stock Titan
Agilent (NYSE: A) director reports no direct stock - Stock Titan
Is Agilent Technologies Stock Outperforming the Dow? - inkl
AGILENT TECHNOLOGIES INC : UBS CUTS TO NEUTRAL FROM BUY - Bitget
Agilent Technologies Director Mikael Dolsten Reports Sale of 634 Shares - Kalkine Media
Agilent Technologies stock holds near 52-week high after guidance lift - ad-hoc-news.de
Agilent Technologies Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Agilent Technologies (NYSE: A) director unloads 634 shares in early September trade - Stock Titan
Agilent Technologies Shares Fall After UBS Downgrade - marketscreener.com
UBS Downgrades Agilent Technologies to Neutral From Buy, $165 Price Target - Moomoo
Agilent Technologies (NYSE: A) Announces 2027 Board Leadership Changes with New Chair and Director - Kalkine Media
Agilent appoints new board chair and independent director - The Globe and Mail
Agilent Technologies Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Agilent Technologies Announces Board Chair Retirement and New Director Appointment - Kalkine Media
Agilent names Dow Wilson board chair after Koh Boon Hwee retires - Bitget
Agilent names new board chair, adds director By Investing.com - Investing.com Nigeria
Agilent Names Dow Wilson Board Chair, Adds Former Stryker CFO Glenn Boehnlein - citybiz
Agilent Technologies Inc. Announces Board Changes, Effective September 4, 2026 - marketscreener.com
Agilent names new board chair, adds director - investing.com
Ex-Stryker finance chief joins Agilent (NYSE: A) board as chair role shifts - Stock Titan
Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors - Business Wire
Agilent Technologies stock gains on digital pathology launch and raised 2026 outlook - ad-hoc-news.de
Agilent (A) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Agilent Technologies, Inc. (A) Investor Outlook: Analyzing a 16.30% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews
Price to sales forward of Agilent Technologies, Inc. – MIL:1A - TradingView
Agilent Technologies stock gains as FDA-cleared S540MD slide scanner strengthens digital pathology p - ad-hoc-news.de
Agilent Technologies | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Mikael Dolsten to sell Agilent (NYSE: A) stock - Stock Titan
Worker says Agilent fired him to mask race and age bias - hcamag.com
Agilent Technologies stock gains on digital pathology launch and strong Q3 figures - AD HOC NEWS
Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System - 01net
Agilent Technologies Launches FDA-Cleared S540MD Slide Scanner in US - marketscreener.com
Agilent launches FDA-cleared slide scanner in U.S. market - Investing.com
Agilent launches FDA-cleared slide scanner in U.S. market By Investing.com - Investing.com Australia
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Agilent launches new ICP-MS, GC Systems and Digital Lab Execution platform in India - indianpharmapost.com
Baird Adjusts Price Target on Agilent Technologies to $180 From $169, Keeps Outperform Rating - marketscreener.com
Agilent Unveils Next‑Gen Lab Technologies to Boost India’s Testing Efficiency and Compliance - Indianweb2.com
Agilent Technologies Inc (A) Looks 2.6% Overvalued on GF Value™ - GuruFocus
Agilent: The Recovery Is Real, But So Is The Valuation (NYSE:A) - Seeking Alpha
Finanzdaten der Agilent Technologies Inc-Aktie (A)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):